Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)

INTRODUCTION: An extrafine formulation of the long-acting muscarinic antagonist, glycopyrronium bromide (GB), has been developed for delivery via the NEXThaler dry powder inhaler (DPI). This study assessed the bronchodilator efficacy and safety of different doses of this formulation in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Beeh, Kai M, Emirova, Aida, Prunier, Hélène, Santoro, Debora, Nandeuil, Marie Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973313/
https://www.ncbi.nlm.nih.gov/pubmed/29872288
http://dx.doi.org/10.2147/COPD.S168493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973313/
https://www.ncbi.nlm.nih.gov/pubmed/29872288
http://dx.doi.org/10.2147/COPD.S168493

Ejemplares similares